Coherus reported Q4 net revenue from continuing operations of USD 12.75 million, up 65% year over year, driven primarily by higher LOQTORZI volume. Q4 net loss from continuing operations was USD 46.9 million, or USD 0.39 per share, and non-GAAP net loss from continuing operations was USD 40.42 million, or USD 0.34 per share. For FY 2025, net revenue from continuing operations was USD 42.17 million, up 60%, as LOQTORZI net product revenue rose on volume growth following its January 2024 launch. FY net loss from continuing operations was USD 183.12 million, or USD 1.56 per share, while non-GAAP net loss from continuing operations was USD 159.22 million, or USD 1.36 per share. Coherus ended 2025 with USD 172.1 million in cash, cash equivalents and marketable securities, and said initial data readouts are expected in mid-2026 for Phase 1b tagmokitug/toripalimab dose optimization studies and for the randomized Phase 2 casdozokitug/toripalimab/bevacizumab trial in first-line uHCC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091615PRIMZONEFULLFEED9668611) on March 09, 2026, and is solely responsible for the information contained therein.